Monoclonal Antibody Treatments for Alzheimer's: the Good, the Bad, and the Difficult

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Monoclonal Antibody Treatments for Alzheimer's: the Good, the Bad, and the Difficult

By Robert Przybelski

0 views

January 30, 2024

Disclaimer: On July 2, 2024 the FDA approved Kisunla (donanemab-azbt) injection for the treatment of ...
read more ↘ Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
↖ read less

Comments 0